4//SEC Filing
TAYTON-MARTIN HELEN KATRINA 4
Accession 0001104659-21-003131
CIK 0001621227other
Filed
Jan 10, 7:00 PM ET
Accepted
Jan 11, 9:01 PM ET
Size
8.7 KB
Accession
0001104659-21-003131
Insider Transaction Report
Form 4
TAYTON-MARTIN HELEN KATRINA
Chief Operating Officer
Transactions
- Award
Option to purchase Ordinary Shares
2021-01-11+1,086,816→ 1,086,816 totalExercise: $1.03Exp: 2031-01-11→ Ordinary Shares (1,086,816 underlying) - Award
Option to purchase Ordinary Shares
2021-01-11+242,712→ 242,712 totalExercise: $0.00Exp: 2031-01-11→ Ordinary Shares (242,712 underlying)
Footnotes (4)
- [F1]The exercise price was converted from GBP0.76 based on an exchange rate of U.S. $1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on January 11, 2023 and January 11, 2024, and 60,678 Ordinary Shares on January 11, 2025.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001661780
Filing Metadata
- Form type
- 4
- Filed
- Jan 10, 7:00 PM ET
- Accepted
- Jan 11, 9:01 PM ET
- Size
- 8.7 KB